Your World Empowers Young People to Become Leaders and Agents of Change
The winner of the 2025 Your World competition by British Council Partner Schools is Scoris International School from Uganda. Their project addressing unemployment among women in their country was selected from 642 entries submitted by 3,210 students across 34 countries.
Participants gain crucial skills in problem–solving, communication, and creativity, preparing them to tackle some of...
Your World Empowers Young People to Become Leaders and Agents of Change
The winner of the 2025 ‘Your World’ competition by British Council Partner Schools is Scoris International School from Uganda. Their project addressing unemployment among women in their country was selected from 642 entries submitted by 3,210 students across 34 countries.
Participants gain crucial skills in problem–solving, communication, and creativity, preparing them to tackle...
Your World Empowers Young People to Become Leaders and Agents of Change
The winner of the 2025 Your World competition by British Council Partner Schools is Scoris International School from Uganda. Their project addressing unemployment among women in their country was selected from 642 entries submitted by 3,210 students across 34 countries.
Participants gain crucial skills in problem–solving, communication and creativity, preparing them to tackle some of the world’s...
Your World Empowers Young People to Become Leaders and Agents of Change
The winner of the 2025 ‘Your World’ competition by British Council Partner Schools is Scoris International School from Uganda. Their project addressing unemployment among women in their country was selected from 642 entries submitted by 3,210 students across 34 countries.
Participants gain crucial skills in problem–solving, communication, and creativity, preparing them to tackle...
Dr. Falk Pharma announces positive results from its pivotal phase 3 trial on norucholic acid in primary sclerosing cholangitis
Freiburg, May 7th, 2025
Study results demonstrate superiority of norucholic acid (NCA) over placebo in the combined primary endpoint. There is currently no approved medicine to treat primary sclerosing cholangitis. The results of the 96–week analysis of the NUC–5 trial will be presented at 2025 EASL Congress in Amsterdam.
Dr. Falk Pharma, a research–based pharmaceutical company...
Dr. Falk Pharma gibt positive Ergebnisse seiner zulassungs-relevanten Phase-III-Studie zu Norucholsäure bei primär sklerosierender Cholangitis bekannt
Freiburg, den 7. Mai 2025
Die Studienergebnisse zeigen die Überlegenheit von Norucholsäure (NCA) gegenüber Placebo im kombinierten primären Endpunkt. Es gibt derzeit kein zugelassenes Arzneimittel zur Behandlung von primär sklerosierender Cholangitis. Die Ergebnisse der Studie NUC–5 nach 96 Wochen der Analyse werden auf dem EASL–Kongress 2025 in Amsterdam vorgestellt.
Dr....
Bitget stärkt seine globale Führungsposition und seinen Einfluss auf die Community durch eine starke Präsenz auf der TOKEN2049 in Dubai
DUBAI, Vereinigte Arabische Emirate, May 06, 2025 (GLOBE NEWSWIRE) — Bitget, die führende Kryptowährungsbörse und Web3–Unternehmen, hat eine beeindruckende und aufschlussreiche Woche auf der TOKEN2049 abgeschlossen. Als Gold–Sponsor hat Bitget seine Präsenz durch die Teilnahme an Pressekonferenzen, strategischen Dialogen und gemeinschaftsorientierten Aktivitäten...
Bitget amplia liderança global e impacto na comunidade com forte presença na TOKEN2049 Dubai
DUBAI, Emirados Árabes Unidos, May 06, 2025 (GLOBE NEWSWIRE) — A Bitget, principal corretora de criptomoedas e empresa Web3, encerrou uma semana impactante e esclarecedora na TOKEN2049. Como Patrocinadora Ouro, a Bitget marcou presença com participação de destaque, diálogo estratégico e ativações focadas na comunidade, interagindo com líderes...
Bitget affirme son leadership mondial et son engagement communautaire au TOKEN2049 Dubaï
DUBAÏ, Émirats arabes unis, 06 mai 2025 (GLOBE NEWSWIRE) — Bitget, première bourse de cryptomonnaies et société Web3, a clôturé une semaine marquante et enrichissante au TOKEN2049. En tant que sponsor Gold de l’événement, Bitget a affiché sa présence par une participation de premier plan, un dialogue stratégique...
Antalpha Announces Launch of Initial Public Offering
SINGAPORE, May 06, 2025 (GLOBE NEWSWIRE) — Antalpha Platform Holding Company (“Antalpha” or the “Company”) today announced that it has launched the roadshow for its proposed initial public offering of 3,850,000 ordinary shares with expected pricing between $11.00 and $13.00 per ordinary share. Antalpha expects to grant the underwriters a 30–day option to purchase...
